Monitoring a clinical trial conducted under the food and drug administration regulations allowing a waiver of prospective informed consent: The diaspirin cross-linked hemoglobin traumatic hemorrhagic shock efficacy trial

This publication has 17 references indexed in Scilit:

• Implementing the Food and Drug Administration's Final Rule for Waiver of Informed Consent in Certain Emergency Research Circumstances
  Academic Emergency Medicine, 1999
• The Informed Consent Process and the Use of the Exception to Informed Consent in the Clinical Trial of Diaspirin
  Academic Emergency Medicine, 1999
• Diaspirin Cross-Linked Hemoglobin (DCLHb) in the Treatment of Severe Traumatic Hemorrhagic ShockA Randomized Controlled Efficacy Trial
  JAMA, 1999
• Initial Experience Using the Food and Drug Administration Guidelines for Emergency Research Without Consent
  Annals of Emergency Medicine, 1999
• Emergency Medicine and the Development of the Food and Drug Administration's Final Rule on Informed Consent and Waiver of Informed Consent in Emergency Research Circumstances
  Academic Emergency Medicine, 1998
• Assessment of Exception to Informed Consent
  Published by American Medical Association (AMA) ,1997
• Initial evaluation of diaspirin cross-linked hemoglobin (DCLHb[trademark symbol]) as a vasopressor in critically ill patients
  Critical Care Medicine, 1997
• Informed Consent in Emergency Research
  JAMA, 1995
• Monitoring of clinical trials: Issues and recommendations
  Controlled Clinical Trials, 1993
• Practical issues in data monitoring of clinical trials: Summary of responses to a questionnaire at nih
  Statistics in Medicine, 1993